Full-Time
Confirmed live in the last 24 hours
Provides optical and routing networking solutions
No salary listed
Entry
Company Does Not Provide H1B Sponsorship
Edinburgh, UK + 1 more
More locations: Reading, UK
Ciena specializes in creating optical and routing systems, along with automation software, to help build adaptive networks that cater to the increasing digital demands of users. Their products work by providing high-performance networking solutions that allow clients, such as telecommunications providers, cable operators, governments, and enterprises, to enhance and optimize their network infrastructure. What sets Ciena apart from its competitors is its focus on developing strong, collaborative relationships with customers and partners, which fosters innovation and ensures that their solutions are tailored to meet specific needs. The main goal of Ciena is to deliver value through their advanced networking technologies, enabling richer and more connected experiences for users.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Linthicum, Maryland
Founded
1992
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Employee Assistance Program (EAP)
Company Paid Holidays
Paid Sick Leave
Vacation Time
Join Ciena at MPLS & SRV6 AI Net World Congress 2025 to learn how you can transition to a multi-layer future with Ciena's coherent routing.
Lumen Technologies has chosen Ciena to support its drive to enhance connectivity for cloud and data center operators.
Lumen Technologies (NYSE:LUMN) has selected Ciena (NYSE:CIEN) as its preferred optical vendor to enhance its network infrastructure for AI workloads.
Boston Common Asset Management LLC makes new $256,000 investment in Ciena Co. (NYSE:CIEN).
Transformative Scientific Breakthrough Pioneered by Spencer Trask Co. Venture Osiris TherapeuticsNEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL®, indicated for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children two months and older. This milestone in regenerative medicine was developed and patented by Osiris Therapeutics (Osris), a venture founded by Kevin Kimberlin and Dr. Arnold Caplan, and first backed by Spencer Trask Co